Non-Vitamin K oral anticoagulant treatment – behind the mask there is a story

Mădălina-Ștefana Mihai, Anca Ouatu, Anca Trifan, Cătălin Sfarti

Abstract


Pelvic radiation disease is a term related to complications developed after radiotherapy used for pelvic cancers. Symptomatology can be overt, dull or even absent depending on variable factors. We present the case of a 78-year-old female patient with a declared post-partum hysterectomy, known cardiovascular disease, and fatigue and dizziness as main symptoms. She was diagnosed with pelvic radiation disease only after the symptoms were triggered by a non-vitamin K anticoagulant treatment and carefully reassessed anamnesis. Despite it being a predictable condition in patients receiving pelvic radiation, the disease is underdiagnosed, clinicians often overlooking the scale of the problem by treating the symptoms or by focusing on a small fraction of the disease within their medical branch. The case presented displays the value of shifted focus from survivorship to life quality and the importance of patient-tailored management. Sometimes, complementary therapy uncovers a masked illness which can initially be a real challenge but early diagnosis can lead to a satisfactory medical outcome.

Keywords


pelvic radiation disease; non-vitamin K oral anticoagulants; atrial fibrillation

Full Text:

PDF

References


Morris KA, Haboubi NY. Pelvic radiation therapy: Between delight and disaster. World J Gastrointest Surg 2015; 7(11):279-288.

Dörr W. Radiobiology of tissue reactions. Ann ICRP 2015; 44(1):58-68.

Do NL, Nagle D, Poylin VY. Radiation proctitis: current strategies in management. Gastroenterol Res Pract 2011; 2011:917941.

Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38):2893-2962.

Deutsch D, Boustière C, Ferrari E, Albaladejo P, Morange PE, Benamouzig R. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap Adv Gastroenterol 2017; 10(6):495-505.

Vanneste BG, Van De Voorde L, de Ridder RJ, Van Limbergen EJ, Lambin P, van Lin EN. Chronic radiation proctitis: tricks to prevent and treat. Int J Colorectal Dis 2015; 30(10):1293-1303.

Denham JW, Hauer-Jensen M. Radiation induced bowel injury: a neglected problem. Lancet 2013; 382:2046-2047.

Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2013; 19(1):82-93.

Desai JC, Chatterjee P, Friedman K, Aisenberg J. Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants. Am J Gastroenterol 2016; 3:13-21.

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875–1876.

Connolly SJ, Wallentin L, Ezekowitz MD, et al. The long-term multicenter observational study of Dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study. Circulation 2013; 128:237–243.

Manesh RP, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.

Farcas A, Bataga S, Cijevschi C, et al. Gastrointestinal endoscopy in patients on direct oral anticoagulants. a consensus paper of the Romanian Society of Gastroenterology and Hepatology. J Gastrointestin Liver Dis 2018; 27(2):179-187.

Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of Dabigatran compared with Warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.

Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017; 23(11):1954-1963.

Blech S, Ebner T, Ludwig-Schwellinger E, Stangierand J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, Dabigatran, in humans. Drug Metab Dispos 2008; 36(2):386-399.

Clemens A, Strack A, Noack H, et al. Anticoagulant-related gastrointestinal bleeding - could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med 2014; 46:672–678.

Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11):981-992.




DOI: http://dx.doi.org/10.22551/2018.21.0504.10143

Copyright (c) 2019 Mădălina-Ștefana Mihai, Anca Ouatu, Anca Trifan, Cătălin Sfarti

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

ISSN: 2360-6975